1. Home
  2. TRT vs RNTX Comparison

TRT vs RNTX Comparison

Compare TRT & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trio-Tech International

TRT

Trio-Tech International

HOLD

Current Price

$9.56

Market Cap

105.0M

Sector

Technology

ML Signal

HOLD

Logo Rein Therapeutics Inc.

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$0.87

Market Cap

89.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRT
RNTX
Founded
1958
2001
Country
United States
United States
Employees
N/A
10
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
105.0M
89.0M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
TRT
RNTX
Price
$9.56
$0.87
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
684.0K
579.2K
Earning Date
05-13-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.02
N/A
Revenue
$32,462,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$475.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.42
$0.83
52 Week High
$21.38
$2.18

Technical Indicators

Market Signals
Indicator
TRT
RNTX
Relative Strength Index (RSI) 41.83 38.52
Support Level $9.33 $0.85
Resistance Level $14.78 $1.05
Average True Range (ATR) 1.05 0.07
MACD -0.09 -0.01
Stochastic Oscillator 7.97 13.64

Price Performance

Historical Comparison
TRT
RNTX

About TRT Trio-Tech International

Trio-Tech International is a provider of reliability test equipment and services to the semiconductor and other industries. Its customers are from automotive electronics, industrial electronics, computing and data storage, consumer electronics, and communication markets. The company operated its business in two segments: Semiconductor Back-end Solutions and Industrial Electronics. Geographically, the company operates in the United States (U.S), Singapore, Malaysia, Thailand and China.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: